Zhongtai Securities Co.Ltd(600918) the small and medium-sized market research team combed and studied the companies approved by the CSRC for IPO registration in the latest week of gem and science and Innovation Board (2022.01.24-2022.01.30), and launched the weekly special research report on new shares. This weekly report involves 2 enterprises to be issued on the science and innovation board and 2 enterprises to be issued on the gem:
Kechuang board:
Salem Biology (a19146. SH): the company is a biomedical enterprise focusing on the field of antiserum and antitoxin. It is committed to the research, development, production and sales of preventive and therapeutic drugs in the field of biotoxin and biosafety. The compound annual growth rates of the company’s revenue and net profit in 2017-2020 were 15.68% and – 14.50% respectively, mainly due to the serious covid-19 epidemic in the first half of 2020, which had a great adverse impact on the company’s performance. In 2021h1, the company’s revenue increased by 26.97% year-on-year, and the net profit increased by 71.90%. The epidemic was controlled and the demand in the terminal market recovered. There is a certain market demand in the antiserum antitoxin industry. With the enhancement of the company’s R & D and production capacity promoted by the raised investment project, the antiserum antitoxin product pipeline and product technical quality level are further enriched and improved, and the company is expected to further improve its industry strength and market position.
Sri new material (a20695. SH): the company is a manufacturer of key basic materials and components for high-end application fields such as rail transit, power electronics, aerospace and medical imaging, and provides customers with high-strength and high conductivity copper alloy materials and products, medium and high voltage electrical contact materials and products, high-performance metal chromium powder, CT and Dr ball tube components and other products. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 20.09% and 15.14% respectively, with outstanding growth capacity. The company will benefit from the increasing demand for high-performance copper alloy materials for rail transit traction motors and high-end connecting machines. With the raised investment projects promoting the improvement of the company’s production capacity and the industrialization of core products, the company is expected to further improve its industry strength and market position.
Gem:
Aoki Co., Ltd. (a20590. SZ): the company mainly provides single or comprehensive e-commerce services for brands. Its main business covers three parts: e-commerce sales services, brand digital marketing, technical solutions and consumer operation services. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 44.19% and 31.90% respectively, with outstanding growth capacity. With the increase of the popularity of the network, the change of the structure of Internet users and the expansion of the scale of e-commerce transactions, the e-commerce industry has a large market space, and the raised investment project will build an e-commerce comprehensive service operation center, speed up the brand construction, further promote the enhancement of the company’s R & D and production capacity, and the company is expected to further improve its industry strength and market position.
Taienkang (a20596. SZ): the company is a comprehensive pharmaceutical company integrating agent operation, R & D, production and sales of pharmaceutical products, medical devices and sanitary materials, and providing pharmaceutical technical services and technology transfer. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 16.38% and 42.88% respectively. With the population growth and aging promoting the demand for drugs, the pharmaceutical market has broad market space. At the same time, the raised and invested projects will promote the improvement of the company’s technology R & D ability and the overall level of independent innovation. The company is expected to further improve its profitability and industry position.
Risk tips: 1) the corresponding companies still have the risk of failure to be listed due to special events; 2) The research is only based on the prospectus (Registration draft) and other public materials of the corresponding company, which can not fully reflect the latest situation of the company.
